Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc FIXX.

  • Oxford Biomedica Solutions' Adeno-Associated Virus (AAV) Manufacturing and Innovation Business will be led by Tim Kelly as CEO and Chair of its Board of Directors. 
  • Kelly is currently the Chief Operating Officer of Homology.
  • Oxford will pay Homology $130 million upfront and invest $50 million to fund Oxford Biomedica Solutions in return for an 80% stake.
  • Homology will own 20% of the new company. The transaction is expected to close in Q1 2022.
  • Oxford Biomedica said the venture would broaden its offerings with Homology's expertise in adeno-associated virus manufacturing. 
  • Price Action: FIXX shares are down 2.31% at $2.96 during the market session on the last check Friday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareContractsSmall CapMoversTrading IdeasGeneral